STEVIE (Safety Events In VIsmodEgib), a single-arm, open-label study on the safety of Hedgehog Pathway Inhibitors in advanced basal cell carcinoma Vismodegib: interim analysis of 150 patients

被引：0
|
作者：
Gutzmer, Ralf [1 ]
Leverkues, Martin [2 ,3 ]
Garbe, Claus [4 ]
Herbst, Rudolf [5 ]
Schadendorf, Dirk [6 ]
Kunstfeld, Rainer [7 ]
Hansson, Johan [8 ]
Basset-Seguin, Nicole [9 ]
Page, Damian [10 ]
Mitchell, Lada [10 ]
Hauschild, Axel [11 ]
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Univ Med Mannheim, Mannheim, Germany
[3] Univ Heidelberg, Med Fak Mannheim, D-6800 Mannheim, Germany
[4] Univ Klin Tubingen, Tubingen, Germany
[5] HELIOS Hauttumorzentrum, Erfurt, Germany
[6] Univ Klinikum Essen, Essen, Germany
[7] Med Univ Wien, Vienna, Austria
[8] Karolinska Univ Spital, Stockholm, Sweden
[9] Hop St Louis, Paris, France
[10] F Hoffmann La Roche & Cie AG, Basel, Switzerland
[11] Univ Klinikum Schleswig Holstein, Kiel, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2012年 / 10卷 / 09期
关键词：
D O I：
10.1111/j.1610-0387.2012.08008.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：677 / 677
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
    Yap, Timothy A.
    Nakagawa, Kazuhiko
    Fujimoto, Nobukazu
    Kuribayashi, Kozo
    Guren, Tormod Kyrre
    Calabro, Luana
    Shapira-Frommer, Ronnie
    Gao, Bo
    Kao, Steven
    Matos, Ignacio
    Planchard, David
    Chatterjee, Arkendu
    Jin, Fan
    Norwood, Kevin
    Kindler, Hedy L.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (06): : 613 - 621
  • [42] Successful control of adverse events associated with vismodegib treatment of advanced basal cell carcinoma by recognition of hedgehog pathway activity in normal adult tissue
    Solomon, J. A.
    Chever, D.
    Iarrobino, A.
    Caldwell, C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S185 - S185
  • [43] Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina
    Cozzani, Romina
    del Aguila, Roxana
    Carrizo, Mariano
    Sanchez, Sergio
    Gonzalez, Abel
    Chiacchietta, A.
    Alonso, C.
    Ferrandini, S.
    Molinari, L.
    Fontana
    Murineddu, E. Ruiz
    Del Aguila, R.
    Perelli, L.
    Dupertuis, M.
    Valentini, J.
    Alfaro, R. Diaz
    Mazzuoccolo, L.
    Pelati, M.
    Costa, L.
    Rodriguez, S.
    Ferrario, D.
    Iturbe, J.
    Roy, R. Mendez
    Bozzano, A.
    Romero, A.
    Paez, J. C.
    Berra, A. Colombo
    Streich, G.
    Prisco, Aguilera
    Gonzalez, A.
    Caceres, H.
    Sosa, A.
    Pascale, M.
    Hunis, A.
    Latorre, K.
    Piazzoni, L.
    Di Noto, Lopez
    Oliva, M. E.
    Melamed, M.
    Arrozpide, L.
    Daverede, L.
    Ayala, N.
    Koller, V. Martin
    Vicente, D.
    Maskin, Matias
    Abeldano, A.
    Garbaos, G.
    Palma, G.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2020, 59 (05) : 627 - 632
  • [44] Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
    Sekulic, Aleksandar
    Migden, Michael R.
    Basset-Seguin, Nicole
    Garbe, Claus
    Gesierich, Anja
    Lao, Christopher D.
    Miller, Chris
    Mortier, Laurent
    Murrell, Dedee F.
    Hamid, Omid
    Quevedo, Jorge F.
    Hou, Jeannie
    McKenna, Edward
    Dimier, Natalie
    Williams, Sarah
    Schadendorf, Dirk
    Hauschild, Axel
    BMC CANCER, 2017, 17
  • [45] Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
    Aleksandar Sekulic
    Michael R. Migden
    Nicole Basset-Seguin
    Claus Garbe
    Anja Gesierich
    Christopher D. Lao
    Chris Miller
    Laurent Mortier
    Dedee F. Murrell
    Omid Hamid
    Jorge F. Quevedo
    Jeannie Hou
    Edward McKenna
    Natalie Dimier
    Sarah Williams
    Dirk Schadendorf
    Axel Hauschild
    BMC Cancer, 17
  • [46] Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial
    Kim, Ryul
    Ji, Jun Ho
    Kim, Jung Hoon
    Hong, Jung Yong
    Lim, Ho-Yeong
    Kang, Won Ki
    Lee, Jeeyun
    Kim, Seung Tae
    JOURNAL OF CANCER, 2022, 13 (03): : 1097 - 1102
  • [47] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Ali A. Mokdad
    Hao Zhu
    Muhammad S. Beg
    Yull Arriaga
    Jonathan E. Dowell
    Amit G. Singal
    Adam C. Yopp
    Targeted Oncology, 2019, 14 : 541 - 550
  • [48] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
    Mokdad, Ali A.
    Zhu, Hao
    Beg, Muhammad S.
    Arriaga, Yull
    Dowell, Jonathan E.
    Singal, Amit G.
    Yopp, Adam C.
    TARGETED ONCOLOGY, 2019, 14 (05) : 541 - 550
  • [49] A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis
    Vuppalanchi, Raj
    Gonzalez-Huezo, Ma Sarai
    Payan-Olivas, Ramon
    Munoz-Espinosa, Linda E.
    Shaikh, Farheen
    Cruz-Lopez, Jose L. Pio
    Parmar, Deven
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2021, 12 (04) : E00327
  • [50] Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
    Ito, Shuichi
    Nishiyama, Yuya
    Sugiura, Kenkichi
    Enya, Kazuaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2022, 26 (04) : 350 - 358
12345